Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Following a major outbreak involving the use of tear drops in 13 US states, experts are offering advice on how to protect dry eyes.
Read Full NewsExtended-release buprenorphine injections increase the number of opioid-free days primarily via direct pathways and by suppressing need-related craving, a causal mediation analysis shows.
Moderate-to-severe fatty pancreas is independently linked to a higher risk for incident type 2 diabetes and chronic kidney disease.
1.
Second opinions don't significantly delay breast cancer treatment
2.
Time to Rethink Maintenance Pemetrexed in NSCLC?
3.
Do Anatomy Atlases Reflect Social Inequalities?
4.
Spouses of Cancer Patients May Be at Increased Risk of Suicide
5.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
1.
Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis
2.
Value, Access, and Affordability in Next-Gen Oncology: Navigating Costs, Coverage, and Clinical Impact
3.
Lymphomatoid Papulosis: What You Need to Know
4.
Unlocking the Secrets of Ringed Sideroblasts: A New Frontier in Hematology
5.
Tumor Bed Regeneration and Tissue Reconstruction: Scientific Review and Clinical Insights
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
3.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
5.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge